The U.S. FDA has approved GE HealthCare’s Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent for use in pediatric patients. The latest approval ...
OPTISON (perflutren protein-A microspheres) injectable suspension by GE Healthcare The FDA has approved updated labeling for GE Healthcare's Optison (perflutren protein-type A microspheres injectable ...
PRINCETON, NJ, June 13, 2011 – Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison™ (Perflutren Protein-Type A Microspheres ...
GE Healthcare Medical Diagnostics announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in ...
GE Healthcare today announced important changes to the U.S. product label for Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the ...
GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to remove hypersensitivity to ‘blood and blood ...
Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ...
GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback